Increased in tumor longest dimension (18/36)
|
12/18 (67%) had decrease in mean ADC values
|
Increased tumor enhancing component (15/36)
|
11/15 (73.3%) showed decreased mean ADC values
|
Increased tumor volume (17/36)
|
Reduction of mean ADC value in 11/17 (64.7%)
|
6/18 (33%) of patients had increase in mean ADC values
|
4/15 (26.7%) showed increased mean ADC values
|
6/17 (35.3%) increase in the mean ADC value
|
No change in tumor size (1/36)
|
Increase in mean ADC value
|
No change in enhancing tumor size (1/36)
|
Increased mean ADC value
|
No change in enhancing tumor volume (1/36)
|
Increased mean ADC value
|
Decrease in tumor longest dimension (17/36)
|
16/17 (94%) of patients showed increased mean ADC values
|
Decreased enhancing tumor sizes (20/36)
|
18/20 (90%) of patients showed increase in mean ADC values
|
Decreased enhancing tumor volume (18/36)
|
16/18 (88.8%) showed increase in mean ADC values
|
1/17 (6%) showed decreased mean ADC value.
|
2/20 (10%) showed decrease in mean ADC values
| |
2/18(11.2%) showed decrease in mean ADC values
|